Aeromedical considerations of malaria prophylaxis with mefloquine hydrochloride.
Mefloquine hydrochloride (WR 142, 490) is a new investigational drug which is indicated for the prevention and treatment of cloroquine-resistant falciparum malaria thought to be resistant to other drugs. Available information on mefloquine, particularly its potential for "quinine-like" side effects, is of aeromedical importance. These side effects, if present, would be expected to alter performance and body physiology to a degree which would compromise flight safety. There is legitimate concern for mefloquine's safe use in aircrewmen. Mefloquine's potential for "quinine-like" side effects should be evaluated before it is routinely used for suppressive prophylaxis in aircrewmen.
D000337:Aerospace Medicine; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D002319:Cardiovascular System / Q000187:drug effects; D004285:Dogs; D006801:Humans; D008168:Lung / Q000187:drug effects; D008288:Malaria / Q000517:prevention & control*; D015767:Mefloquine; D011804:Quinolines / Q000009:adverse effects* / Q000378:metabolism / Q000627:therapeutic use
D000962:Antimalarials; D011804:Quinolines; D015767:Mefloquine